Prof. PeptideProf. Peptide

TB-500

Recovery & Tissue RepairResearch-Grade

Last reviewed: September 20, 2026

Quick Facts

What it is
A lab-made fragment of a natural repair protein (Thymosin Beta-4), studied for wound healing, muscle and tendon recovery, and cardiac and corneal repair.
How it's taken
Subcutaneous injection, once or twice weekly
Half-life
Not characterized — no pharmacokinetic study of the TB-500 fragment was found
Typical research dose
2.0–2.5 mg twice weekly to load, then ~2.0 mg weekly; 6–8 week cycles
Research status
Not FDA-approved — research use only.
On this page
  1. 1.Where to source TB-500
  2. 2.What is TB-500?
  3. 3.How does TB-500 work?
  4. 4.What is TB-500 used for?
  5. 5.How long does TB-500 take to work?
  6. 6.How is TB-500 dosed?
  7. 7.How is TB-500 administered?
  8. 8.What does TB-500 stack well with?
  9. 9.What are the side effects of TB-500?
  10. 10.Does TB-500 interact with other drugs?
  11. 11.How should TB-500 be stored?
  12. 12.What are the limitations of TB-500 research?
  13. 13.TB-500 FAQ
  14. 14.References
  15. 15.Published Studies
  16. 16.In the News

Where to source TB-500

TB-500 is not FDA-approved and is sold by specialty research peptide vendors. The vendors highlighted below have been vetted for transparent third-party testing, traceable batch documentation, and verified discount codes.

Capstone Peptides50% off
Professor's Pick

Accumark Labs · digital COAs

Shop Capstone Peptides
Amino Club40% off

ILS Laboratories · batch COAs

Shop Amino Club
Peptide Partners10% off
Professor's Pick

Kovera, Chromate and BioRegen · certificates checked at each lab

Shop Peptide Partners
Glacier Aminos10% off

Batch-traceable COAs · cold-chain shipping

Shop Glacier Aminos
Compare prices across 53 vendors

Also stocking TB-500

BioLongevity Labs, Crownwell Research, EZ Peptides, Fusion Peptide — each carries a current price row for this compound.

Compare all 53 vendors stocking TB-500

See all 88 verified vendors

What is TB-500?

TB-500 is a synthetic fragment of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide found in virtually all mammalian cells. TB-500 corresponds to the active Tβ4 17-23 region of Thymosin Beta-4 (gene symbol TMSB4X). Unlike the full Thymosin Beta-4 protein, TB-500 is a shorter active fragment that's easier to synthesize and study. Researchers have studied it for over two decades, primarily for wound healing, cardiac repair, and corneal regeneration. It's commonly paired with BPC-157 in tissue-repair research protocols (the Wolverine Stack). New to peptide research? Start with the basics

Reported benefits:

  • Accelerated wound healing in dermal, corneal, and cardiac tissue (animal models)
  • Promotes new blood vessel formation (angiogenesis)
  • Reduces fibrosis and scarring during repair
  • Anti-inflammatory effects through NF-κB pathway modulation
  • Mobilizes stem and progenitor cells to injury sites
  • Pairs synergistically with BPC-157 in musculoskeletal repair research

Common research dose: Most research protocols use 2.0–2.5 mg subcutaneously twice weekly for the first 4 weeks (loading phase), then 2.0 mg once weekly for maintenance. Total cycle length is typically 6–8 weeks, followed by 4–6 weeks off.

Where to buy: PP maintains a vetted list of peptide vendors with verified discount codes. See Verified Discount Codes for current options.

How does TB-500 work?

TB-500's primary mechanism is binding monomeric G-actin to maintain a ready pool for cytoskeletal remodeling — which is critical for cellular migration. This allows repair cells (fibroblasts, endothelial cells, keratinocytes, and bone marrow progenitor cells) to migrate toward injury sites and rebuild tissue. TB-500 also stimulates angiogenesis, mobilizes stem cells, reduces inflammation through NF-κB modulation, and activates the Wnt/β-catenin pathway. These mechanisms are complementary to BPC-157's growth-factor-driven repair, which is why the two are commonly stacked.

  1. Actin Sequestration [1]. TB-500's primary mechanism is binding monomeric G-actin and maintaining a ready pool for cytoskeletal remodeling. This is critical for cellular migration — moving repair cells (fibroblasts, endothelial cells, keratinocytes, and stem cells) toward injury sites.
  2. Angiogenesis Promotion [2]. TB-500 stimulates endothelial cell proliferation and tube formation, which builds new capillaries to supply oxygen and nutrients to healing tissue. This is the structural complement to BPC-157's growth factor-driven angiogenesis.
  3. Stem Cell Mobilization [3]. TB-500 mobilizes bone marrow stem and progenitor cells, increasing their migration to damaged areas. This is one of the mechanisms behind TB-500's effects in cardiac repair.
  4. Anti-inflammatory Effects [4]. TB-500 reduces inflammatory cytokine production by inhibiting NF-κB signaling. It also reduces apoptosis (cell death) in tissue under stress.
  5. Wnt/β-catenin Pathway Activation [5]. A 2024 study in cutaneous flap models showed TB-500 activates the Wnt/β-catenin pathway, which is one of the body's primary pathways for cell proliferation and tissue homeostasis. This explains how the peptide coordinates multiple repair processes simultaneously.

What is TB-500 used for?

TB-500's research evidence base spans dermal wound healing, cardiac repair after ischemia, corneal regeneration, musculoskeletal repair, hair growth, and inflammatory conditions. The dermal wound and cardiac evidence are the most established. Two RegeneRx-sponsored Phase 2 human trials tested native, full-length Thymosin Beta-4 (not the fragment sold as "TB-500") for epidermolysis bullosa and pressure ulcers; the epidermolysis bullosa trial was terminated for non-efficacy reasons, while the pressure-ulcer trial completed as planned and its results did not show a wound-healing benefit over placebo. Most evidence remains preclinical.

  1. Dermal Wound Healing [4][5]. Multiple animal studies show 42–61% improvement in wound healing rates vs controls. Effects include faster re-epithelialization, increased collagen deposition, and reduced scarring. Effects observed at very low concentrations (as little as 10 pg in laboratory models).
  2. Cardiac Repair [3]. A landmark 2007 Nature study (Bock-Marquette et al.) showed Thymosin Beta-4 was cardioprotective after myocardial infarction in animals. Zhu et al. 2016 (PMID 27288307), a small randomized pilot in 10 STEMI patients, pre-treated endothelial progenitor cells with Tβ4 outside the body for 24 hours before transplanting them; the pre-treated-cell group showed greater improvement in 6-minute walking distance and cardiac function than the untreated-cell control group. Neither Thymosin Beta-4 nor TB-500 was administered to a patient directly in this study — it tested ex vivo cell pre-treatment, not a systemic dose of either compound.
  3. Corneal Wound Healing [6]. Strong preclinical evidence for corneal repair. RegeneRx Biopharmaceuticals took Thymosin Beta-4 through Phase 2 trials for dry eye and corneal wound healing in epidermolysis bullosa (NCT00311766, terminated for lack of patient availability and study-drug expiration).
  4. Musculoskeletal Repair. Animal studies show accelerated tendon, ligament, and muscle healing. The combination with BPC-157 (Wolverine Stack) is the most-studied pairing for musculoskeletal applications.
  5. Hair Growth [7]. A 2015 PLOS ONE study showed Thymosin Beta-4 induces hair growth in mice through stem cell mobilization. Limited human evidence.
  6. Inflammatory and Autoimmune Conditions. RegeneRx's Phase 2 pressure-ulcer trial (NCT00382174, applied topical Thymosin Beta-4, not injectable TB-500) completed with results posted in 2010: wound healing by Day 84 occurred in 3 of 18 placebo patients (16.7%) versus 8 of 54 Thymosin Beta-4 patients (14.8%) across three combined doses — no benefit over placebo was shown. Animal studies in inflammatory conditions separately show wound-healing benefits; the human pressure-ulcer result does not confirm this translates to humans.

How long does TB-500 take to work?

TB-500 effects are sometimes reported to develop gradually over the first 2–4 weeks of consistent dosing, though no trial or label has been identified establishing this timeframe. Initial doses produce minimal acute sensation. Wound healing acceleration is observed in animal studies starting from the first week of treatment. Most user protocols target a 6–8 week total cycle, with loading-phase improvements becoming noticeable around weeks 2–3.

Initial doses produce minimal acute sensation. Wound healing acceleration is observed in animal studies starting from the first week of treatment. Most user protocols target a 6–8 week total cycle, with loading-phase improvements becoming noticeable around weeks 2–3. Cardiac and corneal applications follow similar timelines in animal models. As with BPC-157, mechanical context (loading on tendons, normal use of healing tissue) is necessary for proper remodeling — TB-500 mobilizes the repair cells but the tissue still has to be challenged to remodel correctly.

How is TB-500 dosed?

No human clinical trial has established a TB-500 dose. The figures below are split into two parts: what the cited literature actually administered, attributed to its own study, species and evidence level; and separately, community-reported practice, labelled as such and never presented as a finding.

Prof. Peptide reports what trials established and what research communities practice, labelled separately. Neither is a recommendation.

Need to calculate a dose?

Use the Prof. Peptide dosage calculator for accurate reconstitution and dosing math.

Open Calculator

What the cited literature administered

Animal model. Biçer et al. (Joint Diseases and Related Surgery, 2026, PMID 42542926) dosed male Sprague-Dawley rats with TB-500 (synthetic thymosin beta-4) at 60 µg/kg/day, intraperitoneally, for four weeks in an Achilles tendon-transection and repair model (N=8 per group). Biomechanical testing showed a significantly higher maximum load to failure than controls (p<0.05), and histopathological scoring showed significantly lower total Bonar scores (p=0.016) and Movin scores (p=0.017), indicating improved tendon architecture and collagen organization. This is Animal Model evidence — no human dose has been established, and no completed human trial has tested a TB-500 dose or schedule for any indication.

Adverse events reported in the same study

Biçer et al. 2026 reported no animal deaths, postoperative infections, wound complications, tendon reruptures, or protocol-related exclusions in any treatment group over the 4-week study.

Community-reported practice (unverified)

Reported research-community practice — attributed to where it circulates, not to the study above, and not independently verified by Prof. Peptide — follows a loading-then-maintenance pattern: a loading phase (weeks 1–4) of 2.0–2.5 mg subcutaneously twice weekly, followed by a maintenance phase (weeks 5–8) of 2.0 mg subcutaneously once weekly, with a 4–6 week off period reported between cycles. This pattern is loosely attributed by the community to RegeneRx's early thymosin beta-4 development, whose own doses for that program were not published for research use. It diverges sharply from the cited animal study above, both in units (a flat mg dose versus the study's own µg/kg dosing) and in route (subcutaneous versus intraperitoneal) — no source was found deriving the community figures from that study's own numbers.

The Prof. Peptide dosage calculator converts between milligram figures and syringe units for a given reconstitution; it performs the arithmetic and does not set a schedule. The TB-500 reconstitution calculator works the same arithmetic against the vial sizes tracked for this compound.

Common question: How often is TB-500 dosed?

How is TB-500 administered?

TB-500 is given as a subcutaneous injection — under the skin, not into muscle — twice weekly during the loading phase and once weekly during maintenance, using a small insulin syringe. For the practical mechanics of insulin syringes, units vs mcg conversion, and subcutaneous technique, see the syringes and injection technique guide.

  1. Route. Subcutaneous injection. Common sites are the abdomen (avoiding a 2-inch radius around the navel), upper outer thighs, and back of the upper arms.
  2. Frequency. Twice weekly during loading phase (weeks 1–4), then once weekly during maintenance (weeks 5–8). Many users inject the same days each week.
  3. Time of day. No study addressed time of day. Community protocols emphasize the same days each week.
  4. With or without food. Either is fine; no fasting requirement.
  5. Site rotation. Rotating sites each injection, with at least an inch between consecutive sites, is the convention for limiting localized irritation.
  6. Missed dose. The reported practice is to administer a missed loading-phase dose if less than 24 hours late, and otherwise to skip to the next scheduled day.
  7. Cycle structure. 6–8 weeks on, 4–6 weeks off is the most common protocol.

Timing context. Community protocols give TB-500 subcutaneously once or twice weekly — very different from BPC-157's daily protocol. No pharmacokinetic study of the TB-500 fragment was found, so whether this schedule maintains stable levels is not known. The two timing variables that matter most are weekly consistency and cycle phase (loading frequency vs maintenance frequency are not interchangeable in the trial-derived protocol).

AspectReported
FrequencyA loading-then-maintenance schedule (twice weekly, then once weekly) is reported community practice, not derived from a trial or label; Prof. Peptide has not independently verified it. No specific week-by-week breakdown is trial- or label-derived.
Best time of dayNo study addressed time of day; community protocols emphasize the same days each week
FoodNo fasting required; inject with or without food
Injection site rotationRotating between the abdomen, thigh, and upper arm without reusing the same site for the next injection is standard subcutaneous-injection practice — documented in FDA-approved injectable labels generally (e.g., Wegovy's and Mounjaro's own instructions to rotate with each dose), not specific to TB-500.
Half-lifeNo pharmacokinetic study of TB-500 found; in humans, IV full-length thymosin beta-4 half-life rose with dose
Steady-stateReached within 2–3 weeks of loading-phase dosing

Reconstitution math. Water volume sets concentration: a lower volume yields a higher concentration and a smaller syringe draw for a given mg amount, and the reverse for a higher volume. TB-500 research vials are typically 5 mg. Because the per-dose amount is large (2 mg), 1–2 mL reconstitution is the common research convention — it keeps the syringe draw within insulin syringe capacity. All units below are measured on a U-100 insulin syringe (100 units = 1 mL). The table assumes a 5 mg vial — for a 10 mg vial, halve the unit values.

BAC waterConcentration0.5 mg dose1 mg dose2 mg dose2.5 mg dose
1 mL5 mg/mL10 units20 units40 units50 units
2 mL2.5 mg/mL20 units40 units80 units100 units
3 mL1.67 mg/mL30 units60 unitsn/a*n/a*

*Draw exceeds standard 100-unit insulin syringe capacity at this reconstitution volume — would require split injections or a lower reconstitution volume.

Units vs mcg. At a 5 mg vial, each unit drawn delivers 50 mcg of TB-500 at 1 mL reconstitution, 25 mcg at 2 mL, and 16.7 mcg at 3 mL — the reconstitution volume determines the mcg-per-unit conversion. For a 10 mg vial, double the mcg-per-unit values. For a primer on reading insulin syringes and choosing the right barrel size, see our guide on syringes and injection technique.

What does TB-500 stack well with?

TB-500's most-studied pairing is with BPC-157 — the canonical Wolverine Stack for tissue repair. The two work through complementary mechanisms (growth factor signaling vs cellular migration) without overlapping side-effect profiles. Other natural pairings are GHK-Cu for dermal applications and GH secretagogues for systemic recovery research. Standalone use is also common, particularly for cardiac or corneal-specific applications where the trial-derived protocols are well-defined.

  1. BPC-157 (Wolverine Stack). The most popular pairing. BPC-157 + TB-500 work through complementary mechanisms (growth factor signaling vs cellular migration). See the Wolverine Stack page for the combined protocol.
  2. GHK-Cu. GHK-Cu combined for dermal applications and skin repair research. Different mechanisms with overlapping cell-migration effects.
  3. Resistance training. Natural pairing for musculoskeletal recovery research; mechanical loading is necessary for proper tissue remodeling.
  4. GH secretagogues. MK-677 or the GH Stack combined for systemic recovery research where growth hormone signaling supplements TB-500's cellular repair effects.
  5. Standalone use. Also common, particularly for cardiac or corneal-specific research applications where the original Phase 2 protocols are well-defined.

What are the side effects of TB-500?

TB-500 has a clean safety profile in animal studies. RegeneRx's Phase 2 trials of native Thymosin Beta-4 in pressure ulcers (NCT00382174, completed) and epidermolysis bullosa (NCT00311766, terminated for lack of patient availability and drug expiration) reported comparable adverse-event rates between treatment and placebo. The most-reported user effects are mild injection-site reactions. Theoretical concerns about tumor stimulation from angiogenesis have not been observed in animal or human studies.

Common (most users)

  1. Injection site reactions. Mild redness or irritation, typically resolves within hours.
  2. No common systemic effects. Most users report no acute systemic side effects.

Less common (moderate)

  1. Mild fatigue during loading phase. Inconsistent across users.
  2. Slight nausea. Uncommon.
  3. Mild headache. Inconsistent across users.

Serious (rare)

  1. Long-term human safety data limited. No completed Phase 3 trials.
  2. Theoretical tumor stimulation risk. Angiogenesis activity raises a theoretical concern for users with active malignancy, though no reports of this have appeared in animal or human studies.
  3. Severe allergic reactions. Rare and not commonly reported.

TB-500 has a clean safety profile in animal studies. RegeneRx's Phase 2 trials of native Thymosin Beta-4 in pressure ulcers (NCT00382174, completed) and epidermolysis bullosa (NCT00311766, terminated for lack of patient availability and drug expiration) reported comparable adverse-event rates between treatment and placebo. No completed Phase 3 human safety trials exist.

Common question: What are the side effects of thymosin beta-4?

Does TB-500 interact with other drugs?

TB-500 has no major drug interactions reported in animal studies. Theoretical anticoagulant interaction exists due to angiogenesis/vascular effects, but is not clinically validated. Generally considered safe to combine with other peptides — no contraindications established.

  1. Anticoagulants. Theoretical concern due to TB-500's effects on angiogenesis and vascular function. Not clinically validated.
  2. Insulin and diabetes medications. No documented interactions.
  3. Other peptides. Generally considered safe to combine; no contraindications established.
  4. No major drug interactions reported in animal studies.

How should TB-500 be stored?

  1. Lyophilized (powder) form: Store at -20°C for long-term storage; refrigerate at 2–8°C for short-term.
  2. Reconstituted solution: 2–8°C, refrigerated, is standard practice once dissolved. Prof. Peptide has not identified a manufacturer label, published study, or lab document establishing how long reconstituted research-grade TB-500 remains stable — this page does not state a duration as fact.
  3. Reconstitution uses bacteriostatic water for injection (BAC water). Swirl gently — do not shake.
  4. The reconstituted solution is never frozen.
  5. TB-500 is stored protected from light, in the original carton.
  6. A solution that is cloudy, discolored, or contains particles is discarded.

What are the limitations of TB-500 research?

TB-500 is not FDA-approved by any major regulatory body. Two RegeneRx Phase 2 trials of native Thymosin Beta-4 tested pressure ulcers (NCT00382174, completed, no wound-healing benefit over placebo) and epidermolysis bullosa (NCT00311766, terminated for lack of patient availability and drug expiration). Neither trial tested the injectable TB-500 fragment specifically, and neither established a clinical benefit. Most evidence comes from animal models. The World Anti-Doping Agency prohibits TB-500 in sport under Section S2.

TB-500 is not FDA-approved by any major regulatory body. RegeneRx's Phase 2 pressure-ulcer trial of native Thymosin Beta-4 (NCT00382174) completed as planned in 2010 and did not show a wound-healing benefit over placebo. Its epidermolysis bullosa trial (NCT00311766) was terminated for lack of patient availability and drug expiration, not for safety concerns. Neither trial tested the injectable TB-500 fragment sold to research users.

Most evidence for TB-500 comes from animal models. Human evidence is limited to small pilot studies and the two Phase 2 trials above, neither of which established a clinical benefit. Long-term safety data is absent.

The World Anti-Doping Agency prohibits TB-500 in sport under Section S2 (peptide hormones). Research-grade material is sold for laboratory use only and is not approved for human consumption.

TB-500 FAQ

Is TB-500 the same as Thymosin Beta-4?

No. An anti-doping laboratory's analysis of a commercial TB-500 product (Esposito et al. 2012, PMID 22962027) identified it as the N-terminal acetylated 17-23 fragment of Thymosin Beta-4 (Ac-LKKTETQ) — 7 amino acids, not the full 43-amino-acid protein. This page's dosing and research sections distinguish the two: the RegeneRx human trials tested native, full-length Thymosin Beta-4, not this fragment, and no human trial of TB-500 itself has been identified.

How is TB-500 different from BPC-157?

BPC-157 works through growth factor signaling, nitric oxide modulation, and angiogenesis. TB-500 works through actin polymerization, cellular migration, and stem cell mobilization. The two are commonly stacked because their mechanisms are complementary rather than overlapping. See the BPC-157 vs TB-500 comparison for a side-by-side breakdown.

How long does TB-500 take to work?

Initial effects are subtle and develop gradually. Wound healing acceleration is observed from the first week in animal studies. Most user protocols target a 6–8 week total cycle, with healing improvements becoming noticeable around weeks 2–4.

Why is TB-500 dosed less frequently than BPC-157?

No pharmacokinetic study of the TB-500 fragment was found. The only human pharmacokinetic data is for full-length thymosin beta-4 given intravenously (Ruff 2010), where half-life rose with dose. Community protocols dose TB-500 twice weekly at a larger per-dose amount than BPC-157 (2 mg vs 250 mcg); no study established that schedule.

Is TB-500 safe?

Animal safety data is clean. Two human Phase 2 trials of native Thymosin Beta-4 (not the injectable TB-500 fragment) reported good tolerability at the AE level: one (epidermolysis bullosa) was terminated for non-efficacy reasons unrelated to safety, the other (pressure ulcers) completed as planned with similar adverse-event rates across placebo and treatment arms and no wound-healing benefit shown. Long-term human safety data is absent. Theoretical concerns about angiogenesis and tumor stimulation have not been observed in animal or human studies.

Can I stack TB-500 with BPC-157?

Yes — this combination is called the Wolverine Stack and is the most-studied peptide pairing in tissue-repair research. The two work through complementary mechanisms: BPC-157 drives growth factor signaling and angiogenesis; TB-500 drives cellular migration and stem cell mobilization.

Where can I buy TB-500?

TB-500 is sold by specialty research peptide vendors. PP maintains a list of vetted vendors with verified discount codes — see Verified Discount Codes .

References

  1. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther. 2012;12(1):37-51. https://pubmed.ncbi.nlm.nih.gov/22074294/
  2. Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival, and cardiac repair. Nature. 2004;432(7016):466-72. https://www.nature.com/articles/nature03000
  3. Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-82. https://pubmed.ncbi.nlm.nih.gov/17108969/
  4. Kleinman HK, Sosne G. Thymosin β4 Promotes Dermal Healing. Vitam Horm. 2016;102:53-70. https://pubmed.ncbi.nlm.nih.gov/27450738/
  5. Tao Y, et al. Thymosin β4 improves the survival of cutaneous flaps of rat and activates Wnt/β-catenin pathway. Arch Med Sci. 2024. https://www.archivesofmedicalscience.com/Thymosin-4-improves-the-survival-of-cutaneous-flaps-of-rat-and-activates-Wnt-catenin-pathway/183145/0/article.html
  6. Sosne G, Qiu P, Kurpakus-Wheater M, Wheater M. Thymosin beta-4 and corneal wound healing: visions of the future. Ann N Y Acad Sci. 2010;1194:190-8. https://pubmed.ncbi.nlm.nih.gov/20536468/
  7. Gao X, Liang H, Hou F, et al. Thymosin Beta-4 Induces Mouse Hair Growth. PLoS One. 2015;10(6):e0130040. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0130040
  8. Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. https://pubmed.ncbi.nlm.nih.gov/42542926/
  9. Zhu J, Song J, Yu L, et al. Safety and efficacy of autologous thymosin β4 pre-treated endothelial progenitor cell transplantation in patients with acute ST segment elevation myocardial infarction: A pilot study. Cytotherapy. 2016;18(8):1037-1042. https://pubmed.ncbi.nlm.nih.gov/27288307/
  10. Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. https://pubmed.ncbi.nlm.nih.gov/22962027/

Published Studies

Plain-English summaries of the peer-reviewed studies behind the claims above. Click any title to read the source paper.

Journal of Investigative Dermatology / PubMed · 1999Abstract open
Thymosin Beta4 Accelerates Wound Healing →

Malinda KM, Goldstein AL, Kleinman HK

The foundational study establishing Thymosin Beta-4 (the parent molecule of TB-500) as a potent wound healing factor. In a rat full-thickness wound model, Thymosin Beta-4 administered topically or systemically increased wound re-epithelialization by 42% at day 4 and 61% at day 7 compared to saline controls. Treated wounds also contracted at least 11% more than controls. The researchers found that even tiny concentrations (as little as 10 picograms) stimulated keratinocyte migration up to 300% above baseline in the Boyden chamber assay. This was the paper that first characterized Thymosin Beta-4 as a multi-activity wound healing compound with clinical potential.

Expert Opinion on Biological Therapy · 2012Abstract open
Thymosin Beta-4: A Multi-Functional Regenerative Peptide — Basic Properties and Clinical Applications →

Goldstein AL, Hannappel E, Kleinman HK

A landmark review establishing the scientific foundation for Thymosin Beta-4 clinical development. The paper documents the peptide’s multiple mechanisms — actin sequestration promoting cell migration, stem/progenitor cell mobilization to injury sites, angiogenesis stimulation, anti-inflammatory modulation, and reduction of myofibroblast activity (which reduces scarring). The review notes that these properties provide the scientific rationale for clinical trials in dermal wounds, corneal injuries, cardiac tissue regeneration after ischemic insult, and CNS trauma recovery. This review remains one of the most cited foundational papers for TB-500 research.

Journal of Biochemistry / PubMed · 2011Open Access
Muscle Injury-Induced Thymosin Beta-4 Acts as a Chemoattractant for Myoblasts →

Tokura Y, et al.

This study specifically examined Thymosin Beta-4’s role in skeletal muscle regeneration — directly relevant to TB-500’s applications in sports recovery research. The researchers found that Tβ4 mRNA was upregulated in regenerating muscle fibers following injury, and that both Tβ4 and its sulphoxidized form significantly accelerated wound closure and increased chemotaxis (directed migration) of muscle progenitor cells (myoblasts) toward the injury site. The study established that Thymosin Beta-4 is not just a passive wound healing molecule but an active recruiter of the cells needed to rebuild damaged muscle tissue.

PMC / Cells · 2021Open Access
Utilizing Developmentally Essential Secreted Peptides Such as Thymosin Beta-4 to Remind Adult Organs of Their Embryonic State — New Directions in Anti-Aging Regenerative Therapies →

Maar K, et al.

A compelling 2021 review examining Thymosin Beta-4’s regenerative potential from a developmental biology perspective. The paper documents how Tβ4 is expressed at high levels during embryonic development across the heart, brain, limb buds, and muscles — and how supplementing adult tissue with Tβ4 may reactivate these developmental repair programs. It covers TB-500’s anti-inflammatory mechanism (blocking neutrophil chemotaxis, reducing cytochrome c release, decreasing caspase activation), its role in cardiac regeneration after ischemia, corneal wound healing, and its potential as an anti-aging therapeutic.

PMC / Journal of the American Academy of Orthopaedic Surgeons · 2025Open Access
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions →

PMC Research Group

A 2025 review placing TB-500 in the broader context of therapeutic peptides for orthopaedic injuries. The paper summarizes TB-500’s mechanisms — actin polymerization promotion, progenitor cell recruitment, enhanced cellular migration, anti-inflammatory effects, and proangiogenic activity — and notes its parallels with BPC-157 in terms of tissue repair mechanisms. The review identifies TB-500 as one of several emerging peptides with potential for tendon and muscle repair applications, while acknowledging that formal clinical evidence in humans remains limited and that these compounds are being used ahead of regulatory approval.

Tissue RepairWound HealingCardiac ResearchResearch-Grade

Related Peptides

BPC-157GHK-CuKPVThymosin Alpha-1MK-677

Related Blends

GLOWKLOWWolverine Stack

Comparisons

TB-500 vs Thymosin Beta-4 BPC-157 vs TB-500

We may earn commissions from peptide vendor affiliate links.

Have a question about TB-500? Send us an email